Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue

Brain Tumor Pathology

Volumn 28, Issue 1, 2011, Pages 25-31

  Araki, Yukie ^a   Mizoguchi, Masahiro ^a   Yoshimoto, Koji ^a   Shono, Tadahisa ^a   Amano, Toshiyuki ^a   Nakamizo, Akira ^a   Suzuki, Satoshi O ^a   Iwaki, Toru ^a   Sasaki, Tomio ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Glioblastoma; Immunohistochemistry; O6 methylguanine methyltransferase (MGMT); Quantitative assessment

Indexed keywords

BISULFITE; ENZYME ANTIBODY; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TUMOR PROMOTER;

ACCURACY; ADULT; AGED; ARTICLE; CELL ASSAY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIGITAL IMAGING; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; TISSUE SECTION; TUMOR PROMOTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 79951558173     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-010-0004-2     Document Type: Article

References (32)

1. M Esteller J Garcia-Foncillas E Andion, et al. 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350 1354 1:CAS:528:DC%2BD3cXosFOltLg%3D 10.1056/ NEJM200011093431901 11070098
2. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
3. L Liu SL Gerson 2006 Targeted modulation of MGMT: clinical implications Clin Cancer Res 12 328 331 1:CAS:528:DC%2BD28XmtlGqtg%3D%3D 10.1158/1078-0432. CCR-05-2543 16428468 (Pubitemid 43166117)
4. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas Clin Cancer Res 11 5167 5174 1:CAS:528:DC%2BD2MXmt12qtbg%3D 10.1158/1078-0432.CCR-05- 0230 16033832 (Pubitemid 41003702)
5. M Cankovic T Mikkelsen ML Rosenblum, et al. 2007 A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue Lab Invest 87 392 397 1:CAS:528:DC%2BD2sXjtlWgsLg%3D 17260000 (Pubitemid 46474563)
6. VT Cao TY Jung S Jung, et al. 2009 The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas Neurosurgery 65 866 875 10.1227/01.NEU.0000357325.90347.A1 19834398
7. L Karayan-Tapon V Quillien J Guilhot, et al. 2010 Prognostic value of O(6)-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods J Neurooncol 97 311 322 1:CAS:528: DC%2BC3cXltFOnsLw%3D 10.1007/s11060-009-0031-1 19841865
8. JF Parkinson HR Wheeler A Clarkson, et al. 2008 Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma J Neurooncol 87 71 78 1:CAS:528:DC%2BD1cXivFygtro%3D 10.1007/s11060-007-9486-0 18004504
9. Y Sonoda M Yokosawa R Saito, et al. 2010 O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma Int J Clin Oncol 15 352 358 1:CAS:528: DC%2BC3cXpvFegu7o%3D 10.1007/s10147-010-0065-6 20232102
10. 6-alkylguanine-DNA alkyltransferase in malignant glioma Mol Cancer Ther 5 2531 2539 1:CAS:528:DC%2BD28XhtVOmtbfK 10.1158/1535-7163.MCT-06-0106 17041097 (Pubitemid 44650917)
11. 6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort Cancer 115 4783 4794 1:CAS:528:DC%2BD1MXhtlGns7nK 10.1002/cncr.24546 19637364
12. 6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis Am J Surg Pathol 32 1220 1227 10.1097/PAS.0b013e318164c3f0 18580490
13. 6- methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker Brain Pathol 18 520 532 1:CAS:528:DC%2BD1cXht1CjtLvM 18400046
14. 6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis Neurol Res 25 241 248 1:CAS:528:DC%2BD3sXjsl2qtbY%3D 10.1179/016164103101201445 12739231 (Pubitemid 36520478)
15. M Preusser 2009 MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue Histol Histopathol 24 511 518 1:CAS:528:DC%2BD1MXltFCntrg%3D 19224454
16. J Felsberg M Rapp S Loeser, et al. 2009 Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients Clin Cancer Res 15 6683 6693 1:CAS:528:DC%2BD1MXhtlCjsrfP 10.1158/1078-0432.CCR-08- 2801 19861461
17. EM Grasbon-Frodl FW Kreth M Ruiter, et al. 2007 Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas Int J Cancer 121 2458 2464 1:CAS:528:DC%2BD2sXhtlShtbzM 10.1002/ijc.23020 17691113 (Pubitemid 350022415)
18. M Mollemann M Wolter J Felsberg, et al. 2005 Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors Int J Cancer 113 379 385 10.1002/ijc.20575 15455350 (Pubitemid 40038704)
19. T Nakagawa K Ido T Sakuma, et al. 2009 Prognostic significance of the immunohistochemical expression of O(6)-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas Neuropathology 29 379 388 10.1111/j.1440-1789.2008.00983.x 19019175
20. 6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas J Neurooncol 70 333 340 10.1007/s11060-004- 9170-6 15662974 (Pubitemid 40057961)
21. Y Sonoda T Kumabe M Watanabe, et al. 2009 Long-term survivors of glioblastoma: clinical features and molecular analysis Acta Neurochir (Wien) 151 1349 1358 10.1007/s00701-009-0387-1
22. K Yachi T Watanabe T Ohta, et al. 2008 Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas Int J Oncol 33 469 475 1:CAS:528:DC%2BD1cXht1Wmu7rM 18695875
23. TF Cloughesy K Yoshimoto P Nghiemphu, et al. 2008 Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med 5 e8 10.1371/journal.pmed.0050008 18215105 (Pubitemid 351198268)
24. IK Mellinghoff MY Wang I Vivanco, et al. 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024 1:CAS:528:DC%2BD2MXht1SrtrrE 10.1056/NEJMoa051918 16282176 (Pubitemid 41609094)
25. Kleihues P, Burger PC, Aldape KD, Brat DJ et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD et al (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 33-49
26. M Eoli B Pollo F Bianchessi, et al. 2006 Molecular markers of gliomas: a clinical approach Neurol Res 28 538 541 1:CAS:528:DC%2BD28Xos12jt7c%3D 10.1179/016164106X116827 16808886 (Pubitemid 44141324)
27. R Stupp ME Hegi WP Mason, et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 1:CAS:528:DC%2BD1MXlsVKhs74%3D 10.1016/S1470-2045(09)70025-7 19269895
28. ME Hegi AC Diserens T Gorlia, et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 997 1003 1:CAS:528:DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
29. R Stupp ME Hegi R Mark, et al. 2007 Chemoradiotherapy in malignant glioma: standard of care and future directions J Clin Oncol 25 4127 4136 1:CAS:528:DC%2BD2sXhtlKqsbrE 10.1200/JCO.2007.11.8554 17827463 (Pubitemid 47492957)
30. SL Gerson 2002 Clinical relevance of MGMT in the treatment of cancer J Clin Oncol 20 2388 2399 1:CAS:528:DC%2BD38XktVKrsL4%3D 10.1200/JCO.2002.06.110 11981013 (Pubitemid 34441669)
31. 6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea Biochemistry 35 1328 1334 1:CAS:528:DyaK28XivVequg%3D%3D 10.1021/bi9518205 8573590
32. 6-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon Clin Cancer Res 2 577 584 1:CAS:528:DyaK28XitVylsrw%3D 9816206 (Pubitemid 26099177)